Clinical Report: A Novel Technique for Uveitis

Overview

Dr. Chin Yee discusses the use of XIPERE, a corticosteroid for uveitis, delivered via microneedle technology into the suprachoroidal space.

Background

Uveitis is an autoimmune disease that can lead to significant visual impairment and poses challenges for patients due to unpredictable flare-ups. Effective management is crucial for preserving vision.

Data Highlights

No numerical data provided in the source material.

Key Findings

• XIPERE is delivered into the suprachoroidal space using a microneedle, allowing targeted treatment of inflammation.
• The suprachoroidal delivery method may reduce exposure to the anterior segment.
• Patients treated with XIPERE have shown durability of effects lasting from six months to one year.
• Clinical outcomes indicate vision and anatomical improvements compared to traditional treatments.
• The microneedle technology was developed by Georgia Tech.

Clinical Implications

Understanding the benefits of targeted delivery can inform clinical decision-making in managing uveitis.

Conclusion

The integration of innovative drug delivery systems like XIPERE into clinical practice may enhance the management of uveitis.

Related Resources & Content

1. Ophthalmology Management, 2010 -- Getting Uveitis Under Control –Quickly
2. Retinal Physician, 2020 -- Future Therapies in Uveitis
3. Retinal Physician, 2025 -- Current Pipeline for Noninfectious Uveitis
4. Ophthalmology Management — Uveitic Glaucoma: Techniques and Strategies for Management
5. XIPERE Prescribing Information
6. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis
7. REAL-WORLD INCIDENCE AND MANAGEMENT OF OCULAR HYPERTENSION AFTER SUPRACHOROIDAL TRIAMCINOLONE ACETONIDE INJECTION FOR MACULAR EDEMA IN NONINFECTIOUS UVEITIS - PubMed